REV-ERB raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
As part of his studies into "everyday life" in Nazi Germany, Peukert very strongly argued that it was not a black-and-white picture with many of those taking part in youthful sub-cultures like the Edelweiss Pirates and the Swing Kids, grumbling at work, and attending illegal jazz dance sessions at very least partially endorsed the regime and accepted the "Hitler myth" of a brilliant, benevolent Führer. Peukert noted those who took part in such manifestations of "oppositionality" like the Swing Kids and the Edelweiss Pirates were challenging the regime, but not in such a way as to threaten its hold on power, which is why Peukert called these activities "oppositionality" rather than resistance. In particular, Peukert wrote the Edelweiss Pirates by settling themselves apart from adults and those not from the Rhineland were in fact weakening the traditional German working class sub-culture. Peukert wrote: "The Third Reich cannot have failed to leave its mark on all members of society...Even resistance fighters who did not conform were weighted by the experience of persecution, by the sense of their own impotence, and of the petty compromises that were necessary for survival. The system did its work on the anti-fascists too, and often enough it worked despite the shortcomings of the fascists themselves". Peukert wrote that even those Germans who went into "inner emigration", withdrawing from society as much as possible to avoid dealing with the Nazis as much as they could, helped the system worked.
BRINP2-related peptide (BRP) is a synthetic peptide that displays anti-obesity action similar to semaglutide. It does this without significant muscle loss or anxiety and without impacting bowel movement when administered to mice and pigs. BRP primarily stimulates receptors in the hypothalamus and is consistent with GPCR activation leading to stimulation of CREB and Fos activity in neuronal cells. Researchers at Stanford University derived BRP from the BRINP2 protein, corresponding to amino acids 386–397 (THRILRRLFNLC) of BRINP2. This 12-amino acid peptide is flanked by KK and KR recognition sites within the BRINP2 protein, which are cleaved by proprotein convertases to release the peptide. BRP has been detected in human cerebrospinal fluid by mass spectrometry. Additionally, BRP undergoes C-terminal amidation, resulting in the sequence THRILRRLFNLC-NH2. The non-amidated form of the peptide is inactive.
==== Premenstrual syndrome ==== Historically, progesterone has been widely used in the treatment of premenstrual syndrome. A 2012 Cochrane review found insufficient evidence for or against the effectiveness of progesterone for this indication. Another review of 10 studies found that progesterone was not effective for this condition, although it stated that insufficient evidence is available currently to make a definitive statement on progesterone in premenstrual syndrome.
=== Railway === Several train stations serve Moscow. The city's ten rail terminals (or vokzals) are the following: Belorussky Kazansky Kiyevsky Kursky Leningradsky Paveletsky Rizhsky Savyolovsky Yaroslavsky Vostochny
==== Chinese, Korean, and Japanese-language ==== A 2010 systematic review of the Chinese-language literature found numerous acupuncture-related adverse events, including pneumothorax, fainting, subarachnoid hemorrhage, and infection as the most frequent, and cardiovascular injuries, subarachnoid hemorrhage, pneumothorax, and recurrent cerebral hemorrhage as the most serious, most of which were due to improper technique. Between 1980 and 2009, the Chinese-language literature reported 479 adverse events. Prospective surveys show that mild, transient acupuncture-associated adverse events ranged from 6.71% to 15%. In a study with 190,924 patients, the prevalence of serious adverse events was roughly 0.024%. Another study showed a rate of adverse events requiring specific treatment of 2.2%, 4,963 incidences among 229,230 patients. Infections, mainly hepatitis, after acupuncture are reported often in English-language research, though are rarely reported in Chinese-language research, making it plausible that acupuncture-associated infections have been underreported in China. Infections were mostly caused by poor sterilization of acupuncture needles.
Sources: en.wikipedia.org
Urinalysis — assessment of the visual properties of the urine, chemical evaluation using urine test strips, and microscopic examination Urine creatinine, creatinine clearance — used to assess kidney function Albumin/creatinine ratio — used to diagnose microalbuminuria Urine osmolality — measure of the solute concentration of urine Urine specific gravity ― another measure of urine concentration Urine electrolyte levels — measurement of electrolytes such as sodium and potassium in urine Urine anion gap — used to distinguish between some causes of metabolic acidosis
== AFL career == Monfries was drafted by the Bombers with selection 14 in the 2004 AFL draft. He played football for Walkerville Junior Football Club before moving to Melbourne. He made his debut in Round 1, 2005 against Melbourne, which saw him become the 200th player to have played under coach Kevin Sheedy. Monfries maintained his position in the senior side until round 4, but was dropped for the Anzac Day clash in round 5, against Collingwood and did not play at senior level again until round 12. In round 13 against St Kilda, he kicked two goals and, alongside other young Bombers, played a role in a fifteen-point win. He then went on to play every game for the remainder of the season. In 2006, his second season, Monfries played 21 games, missing only one game due to a minor calf strain. In 2007, Monfries played 20 out of 22 games, omitted on form for two weeks at midseason. He was, however, named as an emergency for both matches and quickly returned to the team due to pressures caused by injuries and suspensions to other key players. In 2009, Monfries became a key player within the Essendon Football Club. He defined his role further as a key position forward and finished second in the club's goalkicking after Matthew Lloyd. On 5 October 2012, Angus told Essendon that he will be leaving and be signing a new four-year deal with Port Adelaide. On 8 October 2012, Essendon announced that Monfries would be traded to Port Adelaide for pick 48. He made his debut for Port Adelaide in round 1, 2013, against Melbourne.
Despite early success, some of the main hinderances of the UPP project were police abuses and disappearances that occurred. One of the most prominent cases of this was the disappearance of Amarildo Souza, a bricklayer from the Rocinha favela. Souza, 42, had been fishing the morning of his disappearance and decided to go into the favela to get produce when he was confronted by UPP officers. Souza was taken for questioning and subsequently never returned home. Souza was well known throughout Rocinha, leading to public outcry at his disappearance and a lack of response by the UPP unit. After more than two months of public outcry, an investigation was opened into his disappearance, where twenty-four UPP officers and the UPP commander were found accused of torture, concealing a body, procedural fraud, and conspiracy. In the subsequent trial, twelve officers would be found guilty of torture, procedural fraud, and concealing a body. Despite the investigation and criminal case, the UPP suffered weakened support from favela residents, who felt both anger and fear at the actions of the local UPP unit. Coupled with insufficient training and poorly strategized growth of the units, the UPP continued to fail as insignificant funding heavily derailed the project, which could not perform what it was intended to. With the weakening of the UPP, criminal organizations could again attempt to reclaim their territories through shootouts and confrontations, but were this time more successful.
== Sources == Clayton, W. Woodford; and Nelson, William. History of Bergen and Passaic Counties, New Jersey, with Biographical Sketches of Many of its Pioneers and Prominent Men., Philadelphia: Everts and Peck, 1882. Harvey, Cornelius Burnham (ed.), Genealogical History of Hudson and Bergen Counties, New Jersey. New York: New Jersey Genealogical Publishing Co., 1900. Van Valen, James M. History of Bergen County, New Jersey. New York: New Jersey Publishing and Engraving Co., 1900. Westervelt, Frances A. (Frances Augusta), 1858–1942, History of Bergen County, New Jersey, 1630–1923, Lewis Historical Publishing Company, 1923. Municipal Incorporations of the State of New Jersey (according to Counties) prepared by the Division of Local Government, Department of the Treasury (New Jersey); December 1, 1958.
Mammals that weigh less than about 18 ounces (510 g; 1.1 lb) are mostly insectivorous because they cannot tolerate the slow, complex digestive process of an herbivore. Larger animals, on the other hand, generate more heat and less of this heat is lost. They can therefore tolerate either a slower collection process (carnivores that feed on larger vertebrates) or a slower digestive process (herbivores). Furthermore, mammals that weigh more than 18 ounces (510 g; 1.1 lb) usually cannot collect enough insects during their waking hours to sustain themselves. The only large insectivorous mammals are those that feed on huge colonies of insects (ants or termites).
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.